小青龙汤通过ILC2s介导JAK/STAT通路治疗变应性鼻炎的机制研究

变应性鼻炎(AR)与免疫和炎症相关，西医治疗最大困难是激素耐药，而小青龙汤对激素耐药类AR患者疗效显著，近年研究发现激素耐药类AR患者外周血中II型固有淋巴细胞(ILC2s)显著增高，因此小青龙汤可能是通过ILC2s发挥治疗作用。本项目组前期研究已证实小青龙汤通过抑制TLR4/NF-κB通路、TSLP表达下调Th2细胞因子治疗AR，发现其可影响固有免疫反应，但具体机制不明。故本项目拟在前期工作基础上，利用OVA致敏髓系细胞敲除RORα转基因小鼠和野生型C57BL/6小鼠、BMDC和CD4+T淋巴细胞共培养，采用共聚焦显微镜、流式细胞分选、免疫荧光、分子印迹、RT-PCR和免疫组化等技术，研究小青龙汤是否通过ILC2s介导JAK/STAT通路抑制DC和CD4+T细胞活化发挥治疗激素耐药类AR，并探讨ILC2s介导JAK/STAT信号通路在DC和CD4+T细胞活化中的作用。

Allergic rhinitis (AR) is associated with immunity and inflammation. The biggest difficulty in Western medicine treatment is steroid resistance, and Xiao-Qing-Long-Tang(XQLT) is effective in patients with steroid-resistant AR. In recent years, it has been found that hormone-resistant AR patients have peripheral blood type 2 innate lymphoid cells (ILC2s) are significantly increased, so XQLT may play a therapeutic role through ILC2s. Previous studies in this project have confirmed that XQLT can treat innate immune response by inhibiting TLR4/NF-κB pathway and TSLP expression down-regulating Th2 cytokine, but the specific mechanism is unknown. Therefore, this project is based on the preliminary work, using OVA sensitized myeloid cells to knock out RORα transgenic mice and wild-type C57BL/6 mice, BMDC and CD4+ T lymphocytes co-culture, using confocal microscope,flow cytometric sorting, immunofluorescence , molecular imprinting, RT-PCR and immunohistochemistry, etc., to study whether XQLT can inhibit the activation of DC and CD4+ T cells through ILC2s-mediated JAK/STAT pathway to treat hormone-resistant AR, and to explore how ILC2s mediate JAK/STAT signaling pathway in DC and CD4+ T cell activation.